DrugPatentWatch Database Preview
Drugs in Development Information for TAK-448
Drug Development Status for TAK-448: Sponsors, patents, clinical trial progress
TAK-448 is an investigational drug.
There have been 314 clinical trials for TAK-448.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2018.
The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).
Summary for TAK-448
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2018-01-01) |
| Vendors | 2 |
Recent Clinical Trials for TAK-448
| Title | Sponsor | Phase |
|---|---|---|
| A Pharmacokinetic and Safety Study of TAK-925 in Participants With Idiopathic Hypersomnia | Millennium Pharmaceuticals, Inc. | Phase 1 |
| A Study of TAK-994 in Participants With Narcolepsy Type 1 | Takeda | Phase 1 |
| Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | Takeda | Early Phase 1 |
Clinical Trial Summary for TAK-448
Top disease conditions for TAK-448
Top clinical trial sponsors for TAK-448
US Patents for TAK-448
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
